Form 4: Vor Biopharma Director Daniella Beckman Acquires 30,000 Stock Options

Director Daniella Beckman of Vor Biopharma Inc. reports the acquisition of 30,000 stock options at an exercise price of $1.61.

Summary

• Daniella Beckman, a director at Vor Biopharma Inc., filed a Form 4 on May 28, 2024, reporting a transaction.
• On May 23, 2024, Beckman acquired 30,000 stock options with an exercise price of $1.61.
• These options vest and become exercisable on the earlier of May 23, 2025, or the next annual meeting of stockholders, contingent upon continued service as a director.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a standard stock option grant, indicating neither positive nor negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, common in the biopharmaceutical industry to align director incentives with company performance.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biopharmaceutical industry.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their director compensation packages.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term commitment.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.
• This incentivizes the director to work towards increasing shareholder value.

Key Dates